Rosario Dueñas

First-Line XELOX Plus Bevacizumab Followed by XELOX Plus Bevacizumab or Single-Agent Bevacizumab as Maintenance Therapy in Patients with Metastatic Colorectal Cancer: The Phase III MACRO TTD Study

Eduardo Díaz‐Rubio, Auxiliadora Gómez‐España, Bartomeu Massutí et al. · The Oncologist · 2012 · 212 citations · Full text

Medicine, Oncology, Pharmacology +12

Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen‐receptor status and predicts for poor prognosis

José J. Gaforio, María José Serrano, Pedro Sánchez‐Rovira et al. · International Journal of Cancer · 2003 · 134 citations · Full text

Medicine, Cell Biology, Oncology +13

First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)

Alfredo Carrato, Albert Abad, Bartomeu Massutí et al. · European Journal of Cancer · 2017 · 88 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

A Carboxylesterase 2 Gene Polymorphism as Predictor of Capecitabine on Response and Time to Progression

Nuria Ribelles, J. Lopez-Siles, A. Bartolomé Sánchez et al. · Current Drug Metabolism · 2008 · 69 citations · Full text

Medicine, Oncology, Pharmacology +17

Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study

Enrique Aranda, M. Valladares, M. Martínez-Villacampa et al. · Annals of Oncology · 2008 · 27 citations

Medicine, Oncology, Pharmacology +12